Emergent BioSolutions (EBS) Tops Q2 EPS by 26c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.02 -3.06%
Revenue Growth %: -45.6%
Financial Fact:
Product sales: 96.7M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -45.6%
Financial Fact:
Product sales: 96.7M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of $0.16, $0.26 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $140.9 million versus the consensus estimate of $174 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bessent: We Make A Market Buying Older Bonds
- Oracle (ORCL) call put ratio 2.3 calls to 1 put with a focus on October calls into quarter results
- B.Riley Reiterates Buy Rating on IonQ, Inc. (IONQ)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
